News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trevena, Inc. Presents Phase 1 Clinical Data for TRV027, a ß-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting



9/7/2012 10:29:57 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure. TRV027 is the most advanced drug in Trevena’s pipeline, and currently the subject of a Phase 2a dose finding study in stable chronic heart failure patients. The Phase 1 first-time-in-human clinical study of the drug was successfully completed in 2010.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES